In 20 12 (Renchen year), China Resources Pharmaceutical achieved a turnover of HK$ 98.6 billion, an operating profit of HK$ 665,438+600 million and total assets of HK$ 85.6 billion, ranking among the top three in the pharmaceutical industry in China.
The products and services provided by China Resources Medicine spread all over 29 provinces (autonomous regions and municipalities). It has a solid industrial foundation and leading edge in the fields of pharmaceutical manufacturing and pharmaceutical circulation, and is committed to building a platform for the coordinated development of the entire industrial chain. China Resources Medicine has a modern production base, distribution center and a high-level R&D center, providing patients and society with products and services in many fields, such as proprietary Chinese medicines, decocted-free traditional Chinese medicines, chemical synthetic medicines, biological medicines, natural medicines, raw material medicine intermediates, nutrition and health products, pharmaceutical equipment, pharmaceutical circulation and so on, and has more than 80 GMP-certified modern production lines, such as cardiovascular, infusion, reproductive health, gene therapy, natural medicines, proprietary Chinese medicines and medical devices.
There are more than 20 products with sales exceeding HK$ 1 billion, and 2 products with sales exceeding HK$ 654.38+billion (999 Ganmaoling and Dong 'e Ejiao Block), with total sales exceeding HK$1.654.38+billion. With 999, Shuanghe, Secco, Dong 'e, Yuting and other well-known trademarks in China. Brand 999 was selected as one of the top 50 most valuable brands in China twice, and Dong 'e Ejiao and other brands were rated as "Top 500 Most Valuable Brands in China".
Focusing on the long-term development in the future, China Resources Medicine has started to invest in building a large-scale biomedical industrial park with international advanced level. Guided by innovative R&D and high-end manufacturing, it is integrating its R&D resources, building an innovation incubation platform, uniformly planning, organizing and implementing the whole-process business development system of R&D, innovation, incubation and industrialization, and organically combining development strategy, market competition and management to continuously enhance the core competitiveness and market competitive position of China Resources Medicine.
China Resources Medicine will adhere to the corporate values of "honesty and trustworthiness, performance-oriented, customer first and grateful return" and the corporate spirit of "pragmatism, passion, professionalism and innovation" of China Resources Group, with the lofty mission of improving the quality of human life, and strive to become a leader in the pharmaceutical industry in China and make contributions to human health.